Immunic (IMUX)
(Delayed Data from NSDQ)
$1.51 USD
+0.02 (1.34%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.51 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
Income Statements
Fiscal Year end for Immunic, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 99 | 119 | 92 | 49 | 37 |
Income After Depreciation & Amortization | -99 | -119 | -92 | -49 | -37 |
Non-Operating Income | 6 | -1 | -1 | 5 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -94 | -120 | -93 | -44 | -35 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -94 | -120 | -93 | -44 | -35 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -94 | -120 | -93 | -44 | -35 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -99 | -86 | -92 | -49 | -37 |
Depreciation & Amortization (Cash Flow) | 0 | 33 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -99 | -119 | -92 | -49 | -37 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 44.32 | 31.82 | 23.65 | 15.66 | 7.72 |
Diluted EPS Before Non-Recurring Items | -2.11 | -2.74 | -3.93 | -2.81 | -4.52 |
Diluted Net EPS (GAAP) | -2.11 | -3.78 | -3.93 | -2.81 | -4.52 |
Fiscal Year end for Immunic, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 22.81 | 23.89 | 23.38 | 23.57 | 25.02 |
Income After SG&A, R&D, and Dept/Amort Expenses | -22.81 | -23.89 | -23.38 | -23.57 | -25.02 |
Non-Operating Income | 1.43 | -5.70 | 1.81 | 0.80 | 1.02 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -21.38 | -29.58 | -21.57 | -22.77 | -24.00 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -21.38 | -29.58 | -21.57 | -22.77 | -24.00 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -21.38 | -29.58 | -21.57 | -22.77 | -24.00 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 101.27 | 97.30 | 44.94 | 44.57 | 44.43 |
Diluted EPS Before Non-Recurring Items | -0.21 | -0.25 | -0.48 | -0.51 | -0.54 |
Diluted Net EPS (GAAP) | -0.21 | -0.30 | -0.48 | -0.51 | -0.54 |